Seven Eight Capital, LP Veracyte, Inc. Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$19.72 - $28.68 $801,440 - $1.17 Million	40,641 New	40,641 $1.12 Million
Q1 2023 May 12, 2023	BUY	$20.58 - $27.89 $320,307 - $434,079	15,564 New	15,564 $347,000
Q3 2022 Nov 10, 2022	BUY	$16.58 - $27.9 $326,145 - $548,820	19,671 New	19,671 $327,000
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $486,132 - $724,551	-13,470 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $423,877 - $630,343	-11,900 Reduced 46.91%	13,470 $626,000
Q2 2021 Aug 13, 2021	BUY	$32.94 - $56.62 $835,687 - $1.44 Million	25,370 New	25,370 $1.01 Million

311

82M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.14B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.